These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 4040847

  • 1. [Vital capillary microscopic examination and transcutaneous pO2-measurements by intravenous prostaglandin E1 infusion].
    Heidrich H, Lammersen T.
    Dtsch Med Wochenschr; 1985 Aug 23; 110(34):1283-5. PubMed ID: 4040847
    [Abstract] [Full Text] [Related]

  • 2. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
    Weiss T, Griesshaber J, Rogatti W, Kistner O, Hsu E, Jansen T, Diehm C.
    Vasa Suppl; 1991 Aug 23; 33():341-2. PubMed ID: 1788749
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy of intravenously applied prostaglandin E1.
    Scheffler P, de la Hamette D, Leipnitz G.
    Vasa Suppl; 1989 Aug 23; 28():19-25. PubMed ID: 2609240
    [Abstract] [Full Text] [Related]

  • 4. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
    Claeys LG, Horsch S.
    Int Angiol; 1996 Dec 23; 15(4):344-9. PubMed ID: 9127776
    [Abstract] [Full Text] [Related]

  • 5. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
    Thum J, Caspary L, Creutzig A, Alexander K.
    Vasa; 1998 May 23; 27(2):100-5. PubMed ID: 9612114
    [Abstract] [Full Text] [Related]

  • 6. Capillary blood cell velocity in periulcerous regions of the lower leg measured by laser Doppler anemometry.
    Stücker M, Huntermann C, Bechara FG, Hoffmann K, Altmeyer P.
    Skin Res Technol; 2004 Aug 23; 10(3):174-7. PubMed ID: 15225267
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K, Rogatti W, Rüttgerodt K.
    Vasa Suppl; 1989 Aug 23; 28():31-8. PubMed ID: 2609242
    [Abstract] [Full Text] [Related]

  • 8. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
    Trifiletti A, Scamardi R, Pizzoleo MA, Sottilotta G, Soraci S, Attinà A, Bagnato L, Barbera N.
    Panminerva Med; 1999 Mar 23; 41(1):15-7. PubMed ID: 10230250
    [Abstract] [Full Text] [Related]

  • 9. [Transcutaneous measures of oxygen partial pressure and capillaroscopic parameters as affected by naftidrofuryl in patients with obliterative arteriopathies, Fontaine stages II-IV].
    Ranft J, Heidrich H, Lammersen T.
    J Mal Vasc; 1987 Mar 23; 12(1):78-81. PubMed ID: 3559415
    [Abstract] [Full Text] [Related]

  • 10. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
    Creutzig A, Arnold A, Caspary L, Thum J, Alexander K.
    Angiology; 1995 May 23; 46(5):357-67. PubMed ID: 7741319
    [Abstract] [Full Text] [Related]

  • 11. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA, Malatino LS, Santonocito M, Messina R, Attinà T, Dell'Arte S, Sarnataro F.
    Int J Clin Pharmacol Ther; 1999 Jul 23; 37(7):347-51. PubMed ID: 10442509
    [Abstract] [Full Text] [Related]

  • 12. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):477-81. PubMed ID: 3062905
    [Abstract] [Full Text] [Related]

  • 13. [Computer-assisted in vivo study of capillary permeability].
    Pilger E.
    Wien Med Wochenschr Suppl; 1985 Jul 15; 94():1-43. PubMed ID: 3868222
    [Abstract] [Full Text] [Related]

  • 14. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
    Mlekusch W, Schillinger M, Sabeti S, Al-Awami M, Gschwandtner M, Minar E.
    Vasa; 2004 Aug 15; 33(3):131-6. PubMed ID: 15461064
    [Abstract] [Full Text] [Related]

  • 15. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
    Hesse WH, Rudofsky G, Peskar BA.
    Wien Klin Wochenschr; 1991 Aug 15; 103(18):554-7. PubMed ID: 1750222
    [Abstract] [Full Text] [Related]

  • 16. Reaction of transcutaneous PO2 and laser Doppler flow signal on intraarterial infusion of PGE1 and nucleotide phosphates in patients with peripheral arterial occlusive disease.
    Caspary L, Creutzig A, Alexander K.
    Vasa Suppl; 1987 Aug 15; 17():17-22. PubMed ID: 3470960
    [No Abstract] [Full Text] [Related]

  • 17. Effects of intravenous and intra-arterial infusions of prostaglandin E1 on canine hindlimb blood flow distribution.
    Lynch TG, Hobson RW, Barbalinardo JP, Kerr JC.
    Surgery; 1984 Jul 15; 96(1):35-41. PubMed ID: 6539953
    [Abstract] [Full Text] [Related]

  • 18. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy.
    Trifiletti A, Bartolone S, Scamardi R, Pizzoleo MA, Attinà A, Sottilotta G, Canobbio V, Soraci S, Barbera N.
    Minerva Cardioangiol; 1999 Mar 15; 47(3):55-8. PubMed ID: 10389444
    [Abstract] [Full Text] [Related]

  • 19. [1st experiences with prostaglandin E1 long-term intra-arterial perfusion in advanced arterial occlusive disease of the lower extremities stage IV].
    Gruss JD, Kawai S, Karadedos C, Bartels D.
    Dtsch Med Wochenschr; 1978 Oct 13; 103(41):1624-5. PubMed ID: 699778
    [No Abstract] [Full Text] [Related]

  • 20. [Transcutaneous and intracutaneous pO2 measurements in the assessment of peripheral arterial occlusive diseases].
    Reuter U, Setlak P, Petrow C, Altmann E, Sinz V.
    Z Gesamte Inn Med; 1987 Apr 01; 42(7):178-82. PubMed ID: 3604349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.